Clinical experience with ethynodiol diacetate 0.5 mg daily as an oral contraceptive.
Femulen, a progestogen only oral contraceptive (ethynodiol diacetate 0.5mg), was evaluated for its contraceptive efficacy and safety in 425 women aged between 16 and 47 years. This was a multicentre open study carried out in General Practice and Family Planning clinics. Five pregnancies were reported, three of which were a result of patient failure. The net pregnancy rate at one year for method failure was 0.5%. No ectopic pregnancy was reported. The median length of the menstrual period was between four and five days and the average length of the non-bleeding interval remained between 24 and 25 days throughout the study. Blood pressure on the whole remained within normal limits. However, there was a small decrease in both systolic and diastolic blood pressure which did not reach significant levels. Body weight was unaltered and no abnormality was found in cervical smears. Femulen was shown to be an effective and acceptable contraceptive in women of varying ages.
Shroff
N E
NE
Pearce
M Y
MY
Stratford
M E
ME
Wilkinson
P D
PD
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D005040:Ethynodiol Diacetate / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D010352:Patient Dropouts; D011247:Pregnancy
D005040:Ethynodiol Diacetate